SANPHARM - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 8,566 | 16,032 | 42,967 | 185,299 | 217,828 | 59,330 | 64,289 | 254,291 |
| Profit before tax | 1,532 | - | - | - | - | - | 5,268 | -16,103 |
| Net profit | 1,509 | 2,871 | -24,817 | 39,579 | 123,800 | 33,614 | 5,004 | -16,103 |
| Equity | -29,333 | 5,963 | -51,279 | -11,700 | 112,230 | 147,361 | 201,952 | 125,224 |
| Liabilities | 42,396 | 35,264 | 184,749 | 433,992 | 415,379 | 337,426 | 321,902 | 212,185 |
| Non-current assets | 0 | 1,680 | 1,680 | 1,680 | 315,811 | 346,874 | 346,874 | 278,319 |
| Current assets | 13,063 | 39,547 | 131,790 | 506,724 | 211,798 | 137,896 | 176,980 | 59,090 |
| Total assets | 13,063 | 41,227 | 133,470 | 508,404 | 527,609 | 484,770 | 523,854 | 337,409 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 43 | 875 | 37,800 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +856500.0% | +87.2% | +168.0% | +331.3% | +17.6% | -72.8% | +8.4% | +295.5% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 11.6% | 7.0% | -18.6% | 7.8% | 23.5% | 6.9% | 1.0% | -4.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | 48.1% | - | - | 110.3% | 22.8% | 2.5% | -12.9% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 17.6% | 17.9% | -57.8% | 21.4% | 56.8% | 56.7% | 7.8% | -6.3% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 17.9% | - | - | - | - | - | 8.2% | -6.3% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | 5.9 | - | - | 3.7 | 2.3 | 1.6 | 1.7 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 8,566 | 16,032 | 12,890 | 82,355 | 54,457 | 32,362 | 47,147 | 254,291 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
SANPHARM - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-08-23 | 2026-08-23 | 3.85 |
| 2026-08-19 | 2026-08-19 | 3.85 |
| 2026-08-16 | 2026-08-17 | 1.72 |
| 2026-08-11 | 2026-08-14 | 1.72 |
| 2025-05-04 | 2025-05-04 | 4.31 |
| 2025-04-30 | 2025-04-30 | 4.26 |
| 2025-04-24 | 2025-04-29 | 4.31 |
| 2025-04-16 | 2025-04-23 | 4.26 |
| 2025-03-18 | 2025-04-15 | 2.13 |
| 2025-03-03 | 2025-03-03 | 4.52 |
| 2025-02-18 | 2025-02-26 | 4.52 |
| 2025-01-16 | 2025-02-17 | 2.39 |
| 2025-01-02 | 2025-01-15 | 0.26 |
| 2024-12-22 | 2024-12-31 | 0.26 |
| 2024-12-17 | 2024-12-20 | 0.26 |
| 2024-09-17 | 2024-09-17 | 2.13 |
| 2024-08-19 | 2024-08-28 | 8.51 |
| 2024-08-05 | 2024-08-18 | 6.38 |
| 2024-07-25 | 2024-08-04 | 4.25 |
| 2024-07-24 | 2024-07-24 | 77.04 |
| 2024-06-18 | 2024-07-23 | 74.92 |
| 2024-06-07 | 2024-06-17 | 72.79 |
| 2024-05-16 | 2024-06-06 | 72.80 |
| 2024-04-23 | 2024-05-15 | 92.40 |
| 2024-04-16 | 2024-04-22 | 91.08 |
| 2024-04-02 | 2024-04-15 | 45.54 |
| 2024-03-18 | 2024-04-01 | 56.13 |
| 2024-02-29 | 2024-03-17 | 10.59 |
| 2024-02-19 | 2024-02-28 | 91.40 |
| 2024-01-16 | 2024-02-18 | 45.86 |
| 2024-01-15 | 2024-01-15 | 0.32 |
| 2023-12-18 | 2024-01-11 | 0.32 |
| 2023-06-16 | 2023-06-29 | 45.56 |
| 2023-05-16 | 2023-06-15 | 0.02 |
| 2023-05-02 | 2023-05-14 | 0.02 |
| 2023-04-26 | 2023-04-28 | 0.02 |
| 2023-04-18 | 2023-04-25 | 45.54 |
| 2023-03-16 | 2023-03-26 | 6.72 |
| 2022-08-23 | 2022-08-24 | 1209.16 |
| 2022-03-16 | 2022-03-20 | 1125.69 |
| 2021-12-16 | 2021-12-29 | 0.20 |
| 2021-11-16 | 2021-12-05 | 0.20 |
| 2021-11-05 | 2021-11-14 | 0.20 |
SANPHARM - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-09-30 | 2025-09-30 | 16.1 |
| 2025-09-28 | 2025-09-29 | 24859.45 |
| 2025-04-24 | 2025-04-24 | 5.42 |
| 2025-04-16 | 2025-04-23 | 720.19 |
| 2025-04-10 | 2025-04-15 | 716.65 |
| 2025-04-09 | 2025-04-09 | 3214.62 |
| 2025-04-08 | 2025-04-08 | 5728.96 |
| 2025-04-02 | 2025-04-07 | 5718.18 |
| 2025-03-28 | 2025-04-01 | 5708.94 |
| 2024-11-28 | 2024-12-01 | 786.47 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
SANPHARM, UAB (code 302788627) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €254.3K and posted a net loss of €16.1K, resulting in a profit margin of -6.3%. This followed a sharp increase in turnover, with revenue up 295.5% year on year and 328.6% over two years. The profit trajectory was more volatile: net profit was €33.6K in 2023, fell to €5.0K in 2024, and turned negative in 2025. At the end of 2025, total assets stood at €337.4K, supported by equity of €125.2K and liabilities of €212.2K. The equity ratio was 37.1%, and debt-to-equity was 1.69. Asset turnover reached 0.75x, while ROE was -12.9% and ROA was -4.8%, reflecting the loss in the latest year. Revenue per employee was €254.3K, with profit per employee at -€16.1K.